OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CC551

Clever Culture Systems Ltd

Biotechnology & Medical ResearchVerified

Clever Culture Systems Ltd has a fully diluted share count of 2,177,122,833, with no difference between basic and diluted shares outstanding, indicating no immediate dilution risk from stock options or convertible securities. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to assess its performance against industry_config preferred metrics or cohort medians. Without these metrics, a direct comparison to industry benchmarks is not feasible. Clever Culture Systems Ltd's revenue concentration by segment and geography is not disclosed in the available data, limiting the ability to evaluate its exposure to specific markets or product lines. This lack of transparency may affect the assessment of its diversification and resilience to regional or segment-specific risks. The company's growth trajectory is not quantified in the outlook, as no numeric deltas or revenue history are provided. This absence of forward-looking guidance and historical performance data hinders the ability to project future growth or assess the company's momentum. The risk assessment indicates a low dilution risk, but the liquidity risk remains unknown. The absence of balance-sheet data and going-concern language in source documents prevents a more detailed evaluation of the company's financial stability and access to capital. Recent events, such as filings or transcripts, are not disclosed in the available data, limiting the ability to assess the company's strategic direction or operational developments. This lack of recent information may affect the understanding of the company's current position and future prospects.

30-day price · CC5-0.00 (-11.5%)
Low$0.02High$0.03Close$0.02As of28 May, 00:00 UTC
Profile
CompanyClever Culture Systems Ltd
TickerCC5.AX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Clever Culture Systems Ltd has a fully diluted share count of 2,177,122,833, with no difference between basic and diluted shares outstanding, indicating no immediate dilution risk from stock options or convertible securities. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to assess its performance against industry_config preferred metrics or cohort medians. Without these metrics, a direct comparison to industry benchmarks is not feasible. Clever Culture Systems Ltd's revenue concentration by segment and geography is not disclosed in the available data, limiting the ability to evaluate its exposure to specific markets or product lines. This lack of transparency may affect the assessment of its diversification and resilience to regional or segment-specific risks. The company's growth trajectory is not quantified in the outlook, as no numeric deltas or revenue history are provided. This absence of forward-looking guidance and historical performance data hinders the ability to project future growth or assess the company's momentum. The risk assessment indicates a low dilution risk, but the liquidity risk remains unknown. The absence of balance-sheet data and going-concern language in source documents prevents a more detailed evaluation of the company's financial stability and access to capital. Recent events, such as filings or transcripts, are not disclosed in the available data, limiting the ability to assess the company's strategic direction or operational developments. This lack of recent information may affect the understanding of the company's current position and future prospects.
Key takeaways
  • Clever Culture Systems Ltd has no immediate dilution risk, as basic and diluted shares are equal.
  • The company's liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
  • Profitability and return metrics are not available, preventing a comparison to industry benchmarks.
  • Revenue concentration by segment and geography is not disclosed, limiting the understanding of diversification.
  • Growth trajectory and historical performance data are not provided, making future projections difficult.
  • Recent events or strategic developments are not disclosed in the available data.
  • --
  • **RATIONALES**:
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.4M-$5.7M-$7.3M-$5.5M
FY-3$2.3M-$7.1M-$6.6M-$4.3M
FY-2$2.1M-$20.5M-$22.5M-$19.5M
FY-1$1.3M-$4.3M-$3.7M-$3.5M
FY0$6.5M-$113.0k$1.7M-$417.0k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$35.7M$24.9M$8.8M
FY-3$31.5M$21.3M$2.8M
FY-2$7.4M-$105.0k$160.0k
FY-1$7.9M$2.4M$789.0k
FY0$10.8M$5.6M$80.0k
PeriodOCFCapExFCFSBC
FY-4-$2.7M-$634.0k-$5.5M
FY-3-$4.9M-$633.0k-$4.3M
FY-2-$1.4M-$305.0k-$19.5M
FY-1-$3.7M-$6.0k-$3.5M
FY0$1.2M-$2.3M-$417.0k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricCC5Activity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity1.2% medp25 0.0% · p75 17.4%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 12:19 UTC#1d50273d
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 14:46 UTCJob: 4609b106